Cipla 's subsidiary InvaGen Pharmaceuticals has entered into an exclusive strategic partnership with Qilu Pharmaceutical for the licensing and supply of QL2107, a biosimilar to Keytruda, specifically for the United States market.

Deal overview

The agreement designates InvaGen as the exclusive partner for QL2107. Under the terms, Qilu Pharmaceutical will handle development, regulatory registration, and supply of the product. Cipla USA Inc. will be responsible for commercialization, leveraging its established presence in the defined territory.

Strategic context

The exclusive nature of the arrangement grants InvaGen a differentiated position in the biosimilar segment for this molecule. The collaboration aligns with Cipla's strategy to build a strong oncology-focused portfolio and expand its biosimilar offerings in coming fiscal years.

Achin Gupta, Managing Director & Global Chief Executive Officer, Cipla, stated that the partnership reflects confidence in the long-term potential of biosimilars. Marc Falkin, Chief Executive Officer, Cipla North America, noted that the company is well-positioned to launch QL2107, subject to regulatory approval.

What the Numbers Show

The deal structure clearly delineates operational responsibilities: Qilu retains control over the capital-intensive phases of development and manufacturing, while Cipla leverages its existing commercial infrastructure in the US. This division allows Cipla to expand its oncology portfolio without assuming upfront R&D costs, relying instead on its commercial execution capabilities to drive revenue post-approval.

Cipla Limited has informed its shareholders and creditors of an order passed by the National Company Law Tribunal (NCLT), Mumbai Bench, on August 18, 2026. The tribunal approved directions for the scheme of amalgamation by absorption of Inzpera Healthsciences Limited into Cipla.

The company issued notices under Section 230(5) of the Companies Act, 2013, to all equity shareholders and unsecured creditors. These notices were dispatched via electronic mode where email addresses were available and through physical mail for others.

Stakeholder Response Window

Stakeholders may submit representations regarding the proposed scheme to the NCLT within 30 days from the date of receipt of the notice. A copy of any representation must also be sent to Cipla’s registered office in Mumbai.

If no response is received within this period, the tribunal will presume that the concerned shareholder or creditor has no objection to the scheme.

Regulatory Context

The NCLT order, dated August 18, 2026, dispensed with the requirement for meetings of equity shareholders and unsecured creditors of the transferee company. As there are no secured creditors involved in the transaction, no meeting of secured creditors was required.

This disclosure is made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The relevant documents, including the notice, NCLT order, and scheme details, are available on the company’s website.